For patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), encorafenib + cetuximab (EC) plus standard ch ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Pfizer's Braftovi combination showed significant survival benefits in a Phase 3 study for BRAF V600E-mutant metastatic ...

A young mother has revealed the symptoms that led to her stage 3 colorectal diagnosis. About 150,000 Americans are diagnosed ...

Chemotherapy has been known to cause damage to peripheral nerves, and sometimes the pain is chronic and severe enough that chemotherapy doses are reduced or discontinued. But prior research has not ...

Recent advancements in imaging techniques and the use of neoadjuvant chemotherapy (NCT) are reshaping how colon cancer is diagnosed and treated. Neoadjuvant chemotherapy refers to the ...

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified ...

In a nutshell A common desert plant called Artemisia herba-alba contains compounds that can effectively kill colorectal ...

Artemisia herba-alba shows promise in combating colorectal cancer, offering new hope through its powerful medicinal ...

Avutometinib plus cetuximab after chemotherapy in patients with KRAS-mutated metastatic colorectal cancer: Results of phase 1 dose escalation. Immune checkpoint inhibitors in digestive tumors with ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...